Untargeted ultra‑high‑resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer

September 2022

Authors: MD, FEBU Anna Ossolińska, MD, PhD, FEBU Tadeusz Ossolinski, MD, PhD, FEBU Krzysztof Ossoliński, Joanna Nizioł, Aneta Płaza-Altamer, Artur Kołodziej, Tomasz Ruman

Abstract

This study reports an untargeted analysis of human serum using ultra‑high‑resolution mass spectrometry coupled with ultra‑high‑performance liquid chromatography. A total of 200 samples (100 bladder cancer patients, 100 controls) were evaluated. The study identified metabolites whose abundances varied significantly across different tumor stages and grades. The authors found 37 serum metabolites that distinguish between low- and high-grade disease. These results suggest that serum metabolite profiling may offer a non‑invasive diagnostic and monitoring tool for bladder cancer

Full link below:

Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer | Scientific Reports